Search

… Alberta. They will review topics related to the extension trial data, as well as key takeaways in relation to the … residency training at the University of Ottawa and Clinical Genetics fellowship training at the University of … production of functional CEP290 protein. In a Phase 1/2 clinical trial sepofarsen reported rapid, significant and …

… QR-110 is currently being evaluated in a Phase 1/2 clinical trial in patients with LCA10. “Given that the p.Cys998X …

… ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 LEIDEN, The Netherlands and … the first patient dosed in the Phase 2/3 ILLUMINATE clinical trial for sepofarsen (formerly named QR-110) in …

… Development Strategy Officer will assume leadership of clinical development at the Company. LEIDEN, the Netherlands, … a RNA therapeutics company with two completed and positive clinical trials, a robust pipeline, and an incredibly …

… Conference and provides an update on the ongoing Phase 1b trial Key Updates An oral presentation on the final results … today announced presentation of data from two clinical studies of QR-010 in oral and poster sessions at the … session “New therapies targeting CFTR: what's new from the clinical trials pipeline?” from 15:00 – 16:30 central …

… Dystrophic Epidermolysis Bullosa and continue to conduct clinical trials with QR-313 in exon 73 as well as progress … 1/2 study to Wings Therapeutics. The ongoing Phase 1/2 trial in patients with DEB due to a mutation in exon 73 will …

… with no approved therapy A first in human Phase 1/2 clinical trial in adRP patients is expected to start in 2019 LEIDEN, …

… describing the previously announced interim results of a clinical trial of QR-110 for the treatment of Leber’s congenital …

… updates At ARVO ProQR will present additional positive pre-clinical proof-of-concept (PoC) data for QR-110 targeting LCA … The company has recently received IND clearance to start clinical trials for this program in both adult and pediatric … ET. ProQR has received IND clearance to start a clinical trial for QR-110 in LCA 10 patients. Children and adults in …

… are currently no therapies commercially available or in clinical development for the vision loss associated with … QR-110 for Leber’s congenital amaurosis 10 currently in clinical trials, and three additional pipeline programs, … 2018, and safety and efficacy results from the Phase 1/2 trial in Usher syndrome patients are expected in 2019. Usher …